Clinical Trials Directory

Trials / Completed

CompletedNCT01335295

Safety Study of Flavocoxid in Duchenne Muscular Dystrophy

Open Pilot Trial to Test the Safety and Tolerability of Flavocoxid in Duchenne Muscular Dystrophy

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
University of Messina · Academic / Other
Sex
Male
Age
4 Years – 16 Years
Healthy volunteers
Not accepted

Summary

Objective of this study is to evaluate safety and tolerability of flavocoxid administered at the daily oral dose of 500 or 1000 mg/die for one year in DMD patients, alone or in association with steroids (deflazacort on alternate days) started at least one year before. The investigators will also perform a multidimensional clinical evaluation covering functional and muscle strength and quality of life (QoL)assessments.

Conditions

Interventions

TypeNameDescription
DRUGFlavocoxidFlavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year

Timeline

Start date
2011-03-01
Primary completion
2013-12-01
Completion
2013-12-01
First posted
2011-04-14
Last updated
2014-02-03

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01335295. Inclusion in this directory is not an endorsement.